David Rind recently revived his blog Evidence in Medicine and has a post up on the SHARP trial. The SHARP trial, which I discussed recently on this blog and on Gooznews, is the basis for Merck’s application for a new indication for its drugs Vytorin (ezetimibe/simvastatin) and Zetia (ezetimibe). David explains why the results in SHARP are consistent with previous evidence on the effect of statins in patients with chronic kidney disease, both pre-dialysis and on dialysis.
Kevin Lomangino has an article up on the “portfolio diet,” which is a diet that emphasizes foods that lower cholesterol. Kevin explains that most of the cholesterol-lowering from this diet comes from the inclusion of foods containing added plant sterols. As I previously discussed on this blog, while plant sterols lower LDL, their effect on cardiovascular events is unknown, making the portfolio diet a bit of a crapshoot healthwise.
Posted on November 6, 2011, in cardiology, plant sterols and tagged cardiovascular events, chronic kidney disease, David Rind, EBM, ezetimibe, Kevin Lomangino, plant sterols, portfolio diet, SHARP trial, statins, Vytorin, Zetia. Bookmark the permalink. 5 Comments.
I couldnt have said it any better to be honest! keep up the awesome work. You are very talented & I only wish I could write as good as you do 🙂 …
My website is about [url=http://cholesteroldiet.blog.fc2blog.net/]Healthy Cholesterol Recipes[/url].
Hello, have you been allowing any advertising on your website? I’d like to purchase a banner for a few months advertising my blog that is closely related. Let me know, or give me an email address that I can reach you at. Many thanks!
@Roseann Sorry, I don’t want any advertising on my site.
Hello, have you been allowing any advertising on your website?